Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial

GENIUS—Gelatine use in ICU and sepsis

Gernot Marx1*, Kai Zacharowski2, Carole Ichai3, Karim Asehnoûne4, Vladimír Černý5, Rolf Dembinski6, Ricard Ferrer Roca7, Dietmar Fries8, Zsolt Molnar9,10, Peter Rosenberger11, Manuel Sanchez-Sanchez12, Tobias Schürholz13, Tamara Dehnhardt14, Sonja Schmier14, Elke von Kleist14, Ute Brauer14 and Tim-Philipp Simon1

Abstract

Background: Sepsis is associated with capillary leakage and vasodilatation and leads to hypotension and tissue hypoperfusion. Early plasma volume replacement is required to achieve haemodynamic stability (HDS) and maintain adequate tissue oxygenation. The right choice of fluids to be used for plasma volume replacement (colloid or crystalloid solutions) is still a matter of debate, and large trials investigating the use of colloid solutions containing gelatine are missing. This study aims to investigate the efficacy and safety of plasma volume replacement using either a combined gelatine-crystalloid regime (1:1 ratio) or a pure crystalloid regime.
**Methods:** This is a prospective, controlled, randomized, double-blind, international, multicentric phase IV study with two parallel groups that is planned to be conducted at European intensive care units (ICUs) in a population of patients with hypovolaemia in severe sepsis/septic shock. A total of 608 eligible patients will be randomly assigned to receive either a gelatine-crystalloid regime (Gelaspan® 4% and Sterofundin® ISO, B. Braun Melsungen AG, in a 1:1 ratio) or a pure crystalloid regime (Sterofundin® ISO) for plasma volume replacement. The primary outcome is defined as the time needed to achieve HDS. Plasma volume replacement will be target-controlled, i.e. fluids will only be administered to volume-responsive patients. Volume responsiveness will be assessed through passive leg raising or fluid challenges. The safety and efficacy of both regimens will be assessed daily for 28 days or until ICU discharge (whichever occurs first) as the secondary outcomes of this study. Follow-up visits/calls will be scheduled on day 28 and day 90.

**Discussion:** This study aims to generate evidence regarding which regimen—a gelatine-crystalloid regimen or a pure crystalloid regimen—is more effective in achieving HDS in critically ill patients with hypovolaemia. Study participants in both groups will benefit from the increased safety of target-controlled plasma volume replacement, which prevents fluid administration to already haemodynamically stable patients and reduces the risk of harmful fluid overload.

**Trial registration:** The European clinical trial database EudraCT 2015-000057-20 and the ClinicalTrials.gov Protocol Registration and Results System ClinicalTrials.gov NCT02715466. Registered on 17 March 2016.

**Keywords:** Colloids, Gelatine, Critically ill, Sepsis, Resuscitation, Fluid management, Capillary leakage

**Background**
Sepsis is one of the major global health issues and is considered a leading cause of death in noncoronary intensive care units (ICUs) [1–3]. Sepsis is associated with increased microvascular permeability (capillary leakage) and vasodilatation that leads to interstitial oedema and intravascular fluid deficit [4]. As a result, tissue perfusion becomes inadequate, and the oxygen supply is decreased, which eventually results in multi-organ failure (MOF) and death [5]. To compensate for the intravascular fluid deficit, suitable fluids may be given intravenously (in the following referred to as plasma volume replacement) to establish a stable blood pressure and a consistent cardiac output with consecutive organ perfusion, i.e. haemodynamic stability (HDS). Early initial plasma volume replacement is recommended in septic patients to maintain appropriate cardiac output and tissue oxygenation [6, 7]. Plasma volume replacement should be target-controlled and individualized to minimize the risk of harmful fluid overload associated with worse outcomes [8–10]. Therefore, as recent data suggest, plasma volume replacement should be guided by flow-based parameters or passive leg raising (PLR), which are useful bedside tests for volume depletion and/or volume responsiveness [11]. The PLR manoeuvre functions as a reversible self-volume challenge of approximately 250 mL of blood. Haemodynamic changes occurring within 30 to 90 s after PLR reliably predict volume responsiveness in a variety of clinical settings [12, 13].

Fluids suitable for plasma volume replacement are either crystalloid solutions (composed of water and electrolytes) or colloid solutions (containing macromolecules dissolved in an electrolyte solution). Crystalloid solutions diffuse easily into the interstitial space (IS), especially in the case of capillary leakage, and may potentially cause tissue oedema [14]. In contrast, colloid solutions contain macromolecules that are unable to pass semipermeable biological membranes and exert colloid-osmotic pressure, retaining water into the intravascular space (IVS). Several studies have shown that colloids remain in the IVS regardless of their molecular weight or the degree of capillary leakage [15–17]. Thus, it is postulated that the amount of fluid needed for plasma volume replacement is lower with colloid solutions than with crystalloid solutions, and consecutive studies may speculate that less fluid is needed to achieve HDS using this method [14, 18].

Currently available colloid solutions for plasma volume replacement contain either human albumin, hydroxyethyl starch (HES, made from potato or maize starch) or gelatine (produced by hydrolyses of bovine collagen). Human albumin is rare and expensive because it is obtained from human sources. HES-containing solutions are contraindicated in septic patients because a variety of clinical trials have suggested negative outcomes with respect to renal function and mortality after the use of HES in critically ill patients [18–20]. Gelatine is thus the only clinically relevant colloid for the treatment of hypovolaemia in septic patients. Since very few trials have been conducted with gelatine in this patient population, the benefit or harm of gelatine cannot be determined from the current evidence [21–24]. Uncertainty about appropriate plasma volume replacement in septic patients, therefore, persists [25]. The current guidelines recommend crystalloids for initial plasma volume replacement.
in critically ill patients [7]. If colloids are used for initial plasma volume replacement in critically ill patients, they are given in a 1:1 to 1:2 ratio with crystalloids in routine clinical practice.

**Study objective**
This study aims to investigate the efficacy of early target-controlled plasma volume replacement using a combined gelatine-crystalloid regime in comparison to a pure crystalloid regime in achieving haemodynamic stability (HDS) in patients with severe sepsis/septic shock (the protocol of this study refers to the former definitions of sepsis, severe sepsis and septic shock as implemented in routine clinical practice at the time of enrolment start) and will provide data on the safety and efficacy of the applied fluid regimens.

**Methods/design**

**Study design**
This is a prospective, controlled, randomized, double-blind, international, multicentric phase IV study with two parallel groups aiming to investigate the efficacy and safety of early target-controlled plasma volume replacement using either a combined gelatine-crystalloid regime (1:1 ratio) or a pure crystalloid regime to achieve haemodynamic stability (HDS) in patients with severe sepsis/septic shock. A total of 608 eligible patients will be randomly assigned to receive the gelatine-crystalloid regimen or the pure crystalloid regimen. The time needed to achieve HDS will be recorded as the primary outcome, and the patients will be examined daily during the subsequent 28 days or until ICU discharge, whichever occurs first, to assess safety and efficacy parameters. Follow-up visits/calls will be scheduled on day 28 and day 90 after randomization. To avoid fluid overload, the administration of investigational medicinal products (IMPs) will be target-controlled. Volume responsiveness will be assessed via the passive leg raising (PLR) manoeuvre or via fluid challenges of up to 500 mL of IMP.

Severe sepsis/septic shock will be diagnosed according to the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) criteria and definitions [1, 26]. These criteria and definitions were generally accepted to diagnose severe sepsis/septic shock at the time of protocol development. After the approval of the study protocol, a new definition of sepsis was published [27]; however, considering the current clinical routine, it was decided to proceed with the study with the approved protocol based on ACCP/SCCM criteria and definitions. Concordance of diagnoses using ACCP/SCCM criteria and the new definitions of sepsis will be checked during analysis.

The populated SPIRIT checklist for this study is provided as Additional file 1.

**Study population, eligibility criteria**
The study will be conducted at European ICUs in a population of male and female patients aged ≥ 18 years with hypovolaemia in severe sepsis/septic shock diagnosed at ICU admission or during the ICU stay. Participating sites are accessible at ClinicalTrials.gov.

Hypovolaemia will be indicated by volume responsiveness, i.e. mean arterial pressure (MAP) or stroke volume index (SVI) increase of >10% after PLR or fluid challenge (see the “Enrolment” section). Patients must be enrolled within 90 min after diagnosis of severe sepsis or septic shock at the ICU or during their ICU stay. The following additional inclusion criteria apply: body weight ≤ 140 kg, antibiotic therapy already started prior to randomization, negative pregnancy test, and signed informed consent/deferred consent.

Reasons for exclusion are the administration of HES, dextran solutions, or > 500 mL of gelatine solutions within 24 h prior to randomization; death expected within the next 48 h (moribund patients as defined by American Society of Anesthesiologists (ASA) ≥ class V [28]); expected need for pressure infusions; confirmed acute SARS-CoV-2 (COVID-19) infection, a requirement for renal support; renal failure; severe congestive cardiac dysfunction; therapeutic heparin medication due to chronic coagulation disease/anticoagulation medication (i.e. partial thromboplastin time > 60 sec); acute burn injuries; severe general oedema; hypersensitivity to the active substance or ingredients of the IMPs; hypersensitivity to galactose-alpha-1,3-galactose (alpha-Gal) or known allergy to red meat (mammalian meat) and offal; hypervolaemia/hyperhydration; hypercalcaemia; metabolic alkalosis; or simultaneous participation in another interventional clinical trial.

**Investigational medicinal products (IMPs), open-label medication**
The investigational medicinal test product Gelaspan® 4% (B. Braun Melsungen AG) is a clear, colourless or slightly yellowish 4% succinylated gelatine solution in an isotonic, fully balanced electrolyte solution. Sterofundin® ISO (B. Braun Melsungen AG), which is a colourless aqueous fully balanced electrolyte solution, serves as an investigational medicinal reference product and for both treatment groups as a noninvestigational medicinal product (open-label medication).

Both products are solutions for infusion provided in 500-ml ready-to-use plastic bottles made of polyethylene (Ecoflac plus®). Patients will receive blinded IMP (Gelaspan® 4% or Sterofundin® ISO) and open-label medication (Sterofundin® ISO) in a 1:1 ratio (i.e. one bottle of...
Blinded IMP, followed by one bottle of open-label medication, and so on). Thus, patients will either receive a combined gelatine-crystalloid regimen (Gelaspan® 4% and Sterofundin® ISO) or a pure crystalloid regime (Sterofundin® ISO only). Since the composition of Sterofundin® ISO reflects the current state of research and current recommendation for fluid replacement in septic patients [29, 30], it is considered a suitable reference for this study.

Randomization, blinding, and unblinding

Eligible patients will be randomized to either treatment in a 1:1 ratio, stratified for study site and RBC pretreatment (within 24 h prior randomization). Randomization will be based on the patient number, which is assigned at enrolment and indicates country, study site and red blood cell (RBC) pretreatment. A list assigning treatment to each patient number (randomization list) will be generated prior to the initiation of the study using random permuted blocks by an independent biometrician, and sets of emergency envelopes will be prepared.

IMP (Gelaspan® 4% or Sterofundin® ISO) will be blinded, but the noninvestigational medicinal product (Sterofundin® ISO) will be provided in open-label bottles. The blinding of IMP will be performed in advance by the sponsor as a part of the sample manufacturing process. Due to the yellowish colour of gelatine solutions, blinding cannot be assured by covering and labeling alone but additionally requires administration of the study medication via orange infusion lines.

Blinded IMP (Gelaspan® 4% or Sterofundin® ISO) and open-label medication (Sterofundin® ISO) will be supplied by the sponsor in one single box per patient, containing 16 bottles of blinded IMP and 16 bottles of open-label medication (covering the possible maximal amount of IMP and open-label medication required by each patient). To ensure the correct administration sequence, the blinded bottles and open-label bottles will be arranged alternately in the box, starting with the blinded IMP. The bottles must be administered successively. To allow for correct treatment assignments, boxes are labelled with the patient number according to the randomization list before shipment to the study site.

Except for emergency reasons and, if necessary, for review of the unblinded data by the Data Safety Monitoring Board (DSMB, see the “Safety evaluation and reporting of adverse events” section), the study will only be unblinded after the closure of the database and determination of the analysis populations in a blind data review meeting.

Interventions and procedures

Study phases, interventions, and assessments are summarized in the GENIUS study flow diagram (Table 1). Enrolment

Informed consent must be obtained from all patients or their legal representatives, authorized persons or relatives, depending on local regulations. Since the patients will not be able to consent personally and the time required until enrolment in the study will be too short to receive informed consent from a legal representative, authorized person or a family member, informed consent will be obtained within 90 min, according to the deferred consent procedure approved by the respective ethics committees.

Inclusion and exclusion criteria will be checked, and the patient will undergo the PLR manoeuvre or fluid challenge (MAP or SVI increase of > 10%) for an initial test of volume responsiveness.

As soon as possible, the patients/family members/legal representatives will be advised that they have the right to withdraw from the study at any time without prejudice and may be withdrawn at the investigator’s/sponsor’s discretion at any time when it is considered to be in the interest of the patient. Personal consent will be obtained from each patient after regaining competence in decision making or by a family member or legal representative in cases where recovery is not achieved during the study’s duration according to local legal requirements.

Treatment phase

Patients will be randomized with the start of alternate intravenous infusions of blinded IMP (gelatine solution or balanced electrolyte solution) and open-label medication (balanced electrolyte solution). Study medication will be administered until the achievement of first/initial HDS, administration of maximum daily dose (30 ml/kg for IMP and open-label medication, each) or 48 h after randomization, whichever occurs first. During treatment with fluids, MAP will be continuously titrated to a value greater than 65 mmHg with norepinephrine. HDS will be defined as MAP ≥ 65 mmHg and fulfilment of at least two of the following criteria:

- Decrease in arterial lactate within the last 6 h > 10% or lactate < 2.4 mmol/L
- Urine production > 0.5 mL/kg/h
- Central venous oxygen saturation (ScvO2) > 70%

Volume responsiveness will be assessed via changes in MAP (MAP increase > 10% compared to baseline) after PLR, performed 30 min after fluid administration at the latest (maximum 2 bottles of study medication, i.e. 1 bottle of IMP and 1 bottle of open-label medication), as long as no haemodynamic monitoring system is in place. As soon as the system is in place (not later than 6 h after randomization), volume responsiveness will be assessed
### Table 1  GENIUS study flow diagram

| Timepoint          | Study period | Follow-up period |
|--------------------|--------------|------------------|
| Enrolment          | - 90 min     | Day 28           |
| Randomization      | t = 0        | Day 90           |
| Post-randomization | Treatment phase, t = 0 to max. 48 h | Daily assessments, 48 h until ICU discharge or day 28 |
| Follow-up          | Day 28       | Day 90           |

**Enrolment:**
- Eligibility
- Informed consent
- Initial PLR manoeuvre
- Randomization

**Interventions:**
- IMP administration

**Assessments:**

**Demographics and anamnesis**
- Demographic data
- Anamnesis
- Morbidity scores and temperature
- Sepsis

**Primary outcome parameter**
- Time to HDS

**Safety parameters**
- Renal function
- Coagulation
- Hepatic function
- Adverse Events
- Need for blood products
- Concomitant therapies/medication

**Efficacy parameters**
- IMP and open-label medication
- Crystalloids for further volume treatment
- Fluid balance
- Volume responsiveness
- Haemodynamic parameters
- Tissue oxygenation and acid-base balance

**Clinical outcome parameters**
- Fulfilment of ICU discharge criteria
- ICU/hospital LOS
- Indication for RRT
- Days on RRT
- Infection/antibiotic-free days
- Vasopressor-free days
- Ventilator-free days
- Study termination

**Follow-up parameters**
- Colloid therapy
- Last available serum creatinine (SCr)
via changes in SVI (SVI increase > 10%) determined directly after administration of each bottle of study medication (i.e. upon a fluid challenge of 500 mL) or upon PLR. If the patient is no longer volume responsive, administration of study fluids will be stopped, and criteria for HDS will be checked. In case HDS is not established, inotropic therapy (preferably dobutamine) will be given. The administration of study medication will be continued if the patient is volume responsive again (tested via PLR; a fluid challenge can be used only in exceptional cases where the patient’s condition precludes PLR). If the criteria for HDS are fulfilled, treatment with the study medication will be temporarily stopped, and the patient will be further monitored for 4 h by means of blood gas analysis and examination of urine output. If during these 4 h the patient remains haemodynamically stable (criteria fulfilment), there is no need to increase inotrope and/or vasopressor therapy due to sepsis, and a maximum of 1 L of additional study fluids is administered, then the patient will be considered stable, and treatment with study fluids will be stopped. Otherwise, treatment with the study medication will be resumed after testing volume responsiveness and inotropic therapy as required. Fluid needs beyond the total maximum daily dose of study medication, after the initial achievement of HDS or after 48 h of randomization (whichever occurs first), will solely be adjusted by applying a crystalloid solution selected by the treating physician until ICU discharge or day 28 (whichever occurs first). A schematic overview of the treatment phase is provided in the Additional file 2.

**Daily assessments**

Patients will be examined daily starting 48 h after randomization until ICU discharge or day 28 (whichever occurs first), and safety and efficacy variables will be recorded (see the “Methods/design” section, specifically, the “Outcome measures” section).

---

### Table 1 GENIUS study flow diagram (Continued)

| Timepoint       | Study period                  | Follow-up period          |
|-----------------|-------------------------------|---------------------------|
| Enrolment       | Randomization − 90 min t = 0  | Post-randomization t = 0   |
|                 | Treatment phase, t = 0        | to max. 48 h              |
|                 | Daily assessments, 48 h       | until ICU discharge or day 28 |

- Mortality, cause of death
- Quality of life (QoL)\(^1\)
- New RRT, kidney disease

\(^a\)A listing specifying the parameters determined is provided in section Methods/design, subsection Outcome measures
\(^b\)Except Apache II
\(^c\)Except urine output, need and indication for RRT
\(^d\)Lactate only
\(^e\)Date and drug applied, retrospectively from ICU discharge until Day 28 or hospital discharge, whichever occurs first
\(^f\)Taking into account the patient population, the patients’ condition and the effort required to assess QoL, it was decided to collect data on QoL on Day 90 only

---

**Follow-up (FU)**

FUs will be conducted 28 days and 90 days after randomization using a follow-up letter/e-mail or call. If contact is not possible, hospital records will be checked for follow-up information. On day 28, information on mortality, colloid use, and the last serum creatinine value will be assessed. On day 90, mortality, quality of life (measured by the health-related quality of life questionnaire, EQ-5D-5L™, EuroQol Group, [31]) and new kidney disease status will be recorded. If a new renal replacement therapy (RRT) or kidney disease occurred by day 90, any concerned patients might be personally visited and interviewed by the investigator. This optional visit intends to further assess the potential relatedness of kidney injury and study treatment and is explicitly mentioned in the patient information provided to each study participant.

**Study and treatment duration**

**Duration per patient**

The study starts with randomization (i.e. the start of IMP treatment) and ends with ICU discharge or day 28, whichever occurs first. The treatment period will not exceed 48 h.

The patients will be followed up on days 28 and 90 after randomization.

**Duration of the whole study**

The study started in the first quarter of 2016. A recruitment time of 5.5 years is expected.

**Outcome measures**

**Primary outcome**

The primary objective of this study is to investigate the efficacy of early target-controlled plasma volume replacement using a gelatine-crystalloid regime compared to a pure crystalloid regime in achieving HDS in severe sepsis/septic shock patients with hypovolaemia. This will be assessed by measuring the time elapsed between the
start of IMP administration and first/initial HDS as the primary outcome.

**Secondary outcomes**
The secondary objective of this study is to investigate the safety and efficacy of the applied fluid regimes. Safety, efficacy, clinical outcome, and follow-up parameters will be determined as secondary outcomes (see Table 1, GENIUS Study Flow Diagram). A list of all secondary outcomes is provided as Additional file 3.

**Concomitant medication, therapies**
The following concomitant medications are allowed:

- Norepinephrine as vasoactive treatment (titrated to a MAP > 65 mmHg)
- Inotropic treatment (preferably dobutamine)
- Albumin supplementation (not volume replacement) 48 h after randomization until ICU discharge or day 28 (whichever occurs first)
- Crystalloids to cover fluid needs exceeding the total maximum daily dose of IMP and open-label medication during the treatment period (from randomization until the achievement of HDS or 48 h after randomization)
- Blood products (RBCs, fresh frozen plasma (FFP) or platelet concentrates)
- RRT as continuous RRT during the first 48 h after randomization. Thereafter intermitted RRT is allowed.
- Medication as clinically required.

For the whole study duration (i.e. until ICU discharge or day 28, whichever occurs first), the administration of colloids for volume replacement aside from study medication is not allowed.

In the case of protocol deviations, concerned patients will remain in the study for safety reasons but might be excluded from the per protocol set during the blind data review meeting.

**Safety evaluation and reporting of adverse events**
Throughout the clinical trial, particular attention will be given to (serious) adverse events ((S)AEs). The investigator must record all AEs in detail, whether serious or not. A Data Safety Monitoring Board (DSMB) that is not involved in the study and consists of two clinicians and a biometrician will review the data generated throughout the study, preferably in a blinded manner. The DSMB may request unblinding for data review. All SAEs have to be reported to the sponsor within 24 h after awareness, and a notification will be sent to the DSMB. All patients enrolled in this clinical trial must be regarded as critically ill patients in a life-threatening state of disease requiring intensive care events associated with the course of organ dysfunctions as a consequence of severe sepsis/septic shock. All clinically significant abnormal laboratory values as a consequence of underlying disease and/or ICU treatment are not subject to expedited reporting. Expedited reporting applies for death, the suspicion of a causal relationship to the IMP applied, clinically significant abnormal laboratory values, or complications that cannot be explained by the underlying disease or ICU treatment.

SAEs with suspicion of causal relationship to the study treatment that are unexpected according to the available summary of product characteristics (SmPC) of Gelaspan® 4% and Sterofundin® ISO have to be considered suspected unexpected serious adverse reactions (SUSAR). SUSARs are subject to expedited reporting. The sponsor will notify the competent authorities, ethics committees (ECs), and all investigators concerned of SUSARs, in line with pertinent legal requirements.

The DSMB will assess the progress, safety data, and the critical efficacy variables of this study if needed. Based on its review, the DSMB will provide the sponsor with recommendations regarding study modification, continuation, or termination. The entire clinical study might be discontinued upon unexpectedly high-frequency SAEs, the occurrence of SUSARs, or an insufficient number of recruited patients.

Individual patients will be withdrawn by the investigator if haemodynamic monitoring cannot be established or if (S)AE (including pregnancy) and clinically significant abnormal laboratory values lead to non-acceptance of study continuation.

**Sample size calculation, planned interim analysis**
The sample size was based on the assumption of a difference between the gelatine and crystalloid groups. The following hypotheses need to be tested:

\[ H_0 \text{ (null hypothesis)}: \text{HDS [gelatine]} = \text{HDS [crystalloid]} \]
\[ H_A \text{ (alternative hypothesis, one-sided)}: \text{HDS [gelatine]} \neq \text{HDS [crystalloid]} \]

The primary variable, i.e. time to first/initial HDS, was used for sample size calculation. The effect size was estimated based on data from a study comparing the use of HES solution using sodium chloride [20]. Sample size calculation resulted in 253 patients per group, assuming an effect size (difference of means/common standard deviation) of 0.25 (~ 2.5 h/10 h), an α-error of 5% (two-sided), and a power of 80%. Considering a drop-out rate of 20%, the sample size was determined to be 304 patients per group. Since effect size calculation is only considered a rough estimate, an interim analysis for sample
size recalculation is planned upon the inclusion of 400 patients. If the sample size recalculation after 400 patients results in a number exceeding the total number of 608 patients by an extreme amount, then the study will be stopped for futility.

Statistics
All programming of tables, figures, listings, and statistical analyses will be performed using a statistical software package. Statistics will be performed following the principles outlined by guideline E9 of the International Conference on Harmonisation (ICH) and will be outlined in detail in the statistical analysis plan (SAP) finalized before closing the database.

All primary and secondary variables will first be examined by exploratory data analysis and descriptively evaluated. In this setting, the evaluation of structural homogeneity of the treatment groups will be performed for quality assurance. The primary endpoint (time to HDS) will be evaluated with a nonparametric statistical test (Mann-Whitney U test), taking into consideration small sample sizes and possible deviation from a normal distribution. The stratification variables ‘site’ and ‘RBC pretreatment’ will be included in the primary analysis as covariates (in a nonparametric analysis of covariance).

Secondary target variables will also be evaluated with nonparametric tests according to their scaling. Therefore, in the case of a small random sample size or an unbalanced condition, exact tests will be used. Nonparametric multivariate analysis of variance (MANOVA) for repeated measurement will be performed.

Further regressions will be performed as applicable. Several subgroup analyses are planned according to strata (RBC pretreatment, sites), administration of gelatine 24 h prior to randomization, septic shock/severe sepsis, APACHE II score [32], SOFA score [33], transfusion, the establishment of HDS after one episode/at least two episodes of sepsis/septic shock, and diagnosis of sepsis/septic shock at ICU admission/during ICU stay.

All tests will be two-sided with an α-error of 5%. Tests of all secondary variables will be carried out in the area of exploratory data analysis, if applicable. Therefore, corresponding p values are regarded as exploratory, and no adjustments for multiple testing will be made.

All randomized patients will be included in the primary analysis. Missing values will not be imputed. Outliers may be identified using stem-leaf plots and frequency distributions, scatter plots, and box plots. For normally distributed data, values more than three standard deviations away from the mean will be considered outliers. Transformation of the data to mitigate the influence of outliers may be considered. If outliers remain, additional analyses excluding these values will be performed.

An intent-to-treat (ITT) analysis and full analysis set (FAS) are planned. Additionally, a per protocol (PP) or valid case analysis set (VCAS) will be performed, excluding all patients without stopping treatment due to adverse reactions and/or severe protocol violations.

Data registration, monitoring
All data obtained in the context of the clinical trial are subject to data protection. Storage and processing of personal data will be under the provisions set forth by the European Union General Data Protection Regulation (GDPR) 2016/679 and national law. Data processing occurs on the legal basis of the patient’s informed consent to participate in this clinical study or the consent of his/her legal representative/authorized person or relative.

Every effort will be made to collect all data points in the study. The amount of missing data will be minimized by appropriate management of the trial, proper screening of patients, and training of participating investigators and other authorized staff (e.g. nurses), clinical research associates (CRAs), and study managers.

The data generated in this study will be recorded using a computerized system following applicable regulations. The system will generate an individual electronic case report form (eCRF) for each patient participating in the trial. The principal investigator of each study site must ensure the accuracy and completeness of the site data entered in the system using an electronic signature. The eCRF system will guarantee compliance with 21 CFR part 11 [34], data safety, communication security, limited access, and full audit trail.

Authorized, qualified CRAs will visit investigational sites in regular intervals as defined in the monitoring plan to verify adherence to protocol and local legal requirements, perform source data verification, and assist the investigator in his/her study-related activities. An independent audit at the study site may take place at any time during or after the study.

Ethical and legal considerations
This clinical study will be conducted in accordance with the Declaration of Helsinki. It will be conducted in compliance with the protocol, good clinical practice (GCP) (2001/20/EEC, CPMP/ICH/135/95), designated SOPs, and local laws and regulations relevant to the use of investigational new drugs in the country of conduct. This protocol, in its current version 6.0, has been approved by all competent authorities and ethics committees involved.

During the study, all documents that are subject to review will be provided to the institutional ethics committees by the sponsor or the investigator in line with national provisions. Protocol amendments will be submitted to the concerned ethics committees and
capable of life-threatening organ dysfunction caused by a dysregulated systemic inflammatory response syndrome (SIRS) caused by a known or suspected microbial invasion of normally sterile parts of the body [38]. Sepsis associated with infection-induced organ dysfunction or tissue hypoperfusion was rated as severe sepsis, and severe sepsis accompanied by hypotension or the need for vasopressors despite adequate plasma volume replacement was defined as septic shock [39]. In 2016, new definitions and clinical criteria for sepsis and septic shock were published. These definitions describe sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, thereby emphasizing the severity of this systematic illness [27]. According to the new definition, the diagnosis of sepsis already implies organ dysfunction, and the differentiation between sepsis and severe sepsis becomes superfluous. Nevertheless, this protocol refers to the established definitions of sepsis, severe sepsis and septic shock since they were implemented in routine clinical practice at the time enrollment started. To take into account the updated sepsis definition and recommendations regarding diagnostic parameters [27], concordance of diagnoses using established and new diagnostic parameters will be compared in the analysis.

Discussion
This study aims to provide data contributing to answering the question about the right choice of fluid for plasma volume replacement in patients with severe sepsis or septic shock. In contrast to pragmatic studies investigating the safety and efficacy of HES in critically ill patients, the study design of this clinical trial ensures that gelatine containing investigational test products will be administered in line with the recommendations of the manufacturer as outlined in the product information (e.g. contraindications will be respected). Patients will be included within 90 min after the diagnosis of severe sepsis or septic shock to prevent fluid administration prior to randomization, which might bias the study results. Further, fluid administration will be target-controlled; i.e. fluids will be administered to volume-responsive patients only to minimize the risk of fluid overload. This approach also prevents the administration of colloids to already haemodynamically stable patients, which is contraindicated and a limitation of most trials that investigated plasma volume replacement in critically ill patients so far [35]. Study participants in both groups will benefit from target-controlled plasma volume replacement because it increases safety compared to fluid therapy in normal clinical practice, which is most often guided by inadequate haemodynamic parameters such as central venous pressure [29, 36]. The design of this study adequately considers the safety checklist recently published by Meybohm et al. regarding the planning of prospective randomized clinical trials in the field of acute plasma volume replacement in critically ill patients [37].

Patients with severe sepsis or septic shock are the elected study population since they typically require large amounts of fluids [9] and may benefit from the volume expanding properties of colloids. During the last two decades, sepsis has been described as a form of systemic inflammatory response syndrome (SIRS) caused by a known or suspected microbial invasion of normally sterile parts of the body [38]. Sepsis associated with infection-induced organ dysfunction or tissue hypoperfusion was rated as severe sepsis, and severe sepsis accompanied by hypotension or the need for vasopressors despite adequate plasma volume replacement was defined as septic shock [39]. In 2016, new definitions and clinical criteria for sepsis and septic shock were published. These definitions describe sepsis as life-threatening organ dysfunction caused by a dysregulated host response to infection, thereby emphasizing the severity of this systematic illness [27]. According to the new definition, the diagnosis of sepsis already implies organ dysfunction, and the differentiation between sepsis and severe sepsis becomes superfluous. Nevertheless, this protocol refers to the established definitions of sepsis, severe sepsis and septic shock since they were implemented in routine clinical practice at the time enrollment started. To take into account the updated sepsis definition and recommendations regarding diagnostic parameters [27], concordance of diagnoses using established and new diagnostic parameters will be compared in the analysis.

Trial status
This clinical study is currently in the enrolment phase. Enrolment started on 11 April 2016, and the estimated completion date is the end of 2021. The study protocol uses the current version 6.0, dated 16 July 2020. The change history is given in the “Ethics approval and consent to participate” section.
Abbreviations
ACCP/SCCM: American College of Chest Physicians/Society of Critical Care Medicine; APACHE: Acute Physiology and Chronic Health Evaluation; ASA: American Society of Anesthesiologists; CRA: Clinical research associate; CRO: Contract Research Organisation; DSMB: Data Safety Monitoring Board; EC: Ethics committee; eCRF: (electronic) case report form; FAS: Full analysis set; FFP: Fresh frozen plasma; FU: Follow-up; GCP: Good clinical practice; GENIUS: Gelatine Use in ICU and Septis; HDS: Haemodynamic stability; HES: Hydroxyethyl starch; HRQoL: Health-related quality of life; i.a.: Inter alia; i.e.: Id est; ICH: International Conference on Harmonisation; ICU(s): Intensive care unit(s); IMP: Investigational medicinal product; IS: Intersitial space; ITT: Intent-to-treat; IVS: Intravascular space; LOS: Length of stay; MANOVA: Multivariate analysis of variance; MAP: Mean arterial pressure; MOF: Multi-organ failure; PLR: Passive leg raising; PP: Per protocol; RBC: Red blood cell; RRT: Renal replacement therapy; (S)AE: (Serious) adverse event; SAP: Statistical analysis plan; SCR: Serum creatinine; ScvO ₂: Central venous oxygen saturation; SIRS: Systemic inflammatory response syndrome; SnIPC: Summary of product characteristics; SOFA: Sequential Organ Failure Assessment; SUSAR: Suspected unexpected serious adverse reaction; SV: Stroke volume index; VCAS: Valid case analysis set

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05311-8.

Additional file 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.
Additional file 2. Schematic overview of the treatment phase.
Additional file 3. Secondary outcomes.
Additional file 4. List of IECs and CAs.

Acknowledgements
The authors would like to thank Dr. Katharina Achilles, B. Braun Melsungen AG, for medical writing assistance.

Data Safety Monitoring Board
The members of the Data Safety Monitoring Board (DSMB) are Prof. Dr. Donat R. Spahn University Hospital, Zurich, Switzerland; Prof. Dr. Pierre-François Laterre, Cliniques Universitaires Saint-Luc Brussels, Belgium; and Holger Stammer, Pharmalog-Institut für klinische Forschung GmbH, Ismaning, Germany.

Authors’ contributions
All authors made substantial intellectual contributions to the study conception and design and have been involved in drafting the manuscript. GM and TPS revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding
In this clinical study, B. Braun Melsungen AG, Carl-Braun Str. 1, D-34212 Melsungen acts as the sponsor, funder and data holder of this study. Additionally, it is the manufacturer of IMP, as well as the co-author and medical writer of this manuscript. B. Braun Melsungen AG organized protocol development and contracted a contract research organization (CRO) for clinical trial application, monitoring, and collection/analysis of study data. Investigational tests and reference products will be produced and delivered by B. Braun Melsungen AG to all participating sites. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
Not applicable; no datasets are included in this study protocol.

Declarations
Ethics approval and consent to participate
The study protocol was initially approved in version 2.0, dated 30 November 2015, by the Ethics Committee of the Medical University of Innsbruck, Austria (AN2015-0179 352/21), the Ethics Committee of the Institute of Clinical and Experimental Medicine and Thomayer Hospital with Multicentre Competence, Czech Republic (M-1544), the Ethics Committee at the RWTH Aachen Faculty of Medicine, Germany (EK 206/15), the Comité de Protection des Personnes Sud Méditerranée V, France (15/081), and the Ethics Committee for Clinical Pharmacology, Hungary (OGYH/28865/2015). After the study started, the protocol was amended three times via global protocol amendments. The first global protocol amendment aimed to improve patient recruitment (i.e. inclusion of three study sites in Spain and an additional site in Germany), to harmonize wording discrepancies and to clarify the documentation of some variables (protocol version 3.0, dated 2 May 2017). This amendment was approved by the ethics committees of the Medical University of Innsbruck (17 November 2017), the Institute of Clinical and Experimental Medicine and Thomayer Hospital (9 August 2017), the RWTH Aachen (26 July 2017), and the Ethics Committee for Clinical Pharmacology (6 September 2017). As study sites in France completed recruitment before the compilation of the first global amendment, this amendment was not submitted to the Comité de Protection des Personnes Sud Méditerranée V, The Comités de Ética de la Investigación de los Hospitales Universitarios Virgen Macarena – Virgen del Rocío de Sevilla, Spain; these institutions initially approved the version 3.0 protocol (Acta No. 09/2017). The second global protocol amendment addressed changes to the protocol to reflect updates within the reference safety information (Summary of Product Characteristics) of the investigational test product (Gelaspan 4%) in addition to an update of the investigator list and editorial adaptions (protocol version 4.0, dated 20 July 2018). This amendment was approved by the ethics committees of the Medical University of Innsbruck (24 August 2018), the Institute of Clinical and Experimental Medicine and Thomayer Hospital (12 September 2018), the RWTH Aachen (14 September 2018), and the Comités de Ética de la Investigación de los Hospitales Universitarios Virgen Macarena – Virgen del Rocío de Sevilla, Spain (23 August 2018). As the study was terminated in Hungary on 8 March 2018 (no patients enrolled), this amendment was not submitted to the Ethics Committee for Clinical Pharmacology. The third protocol amendment reflected the prolongation of the expected recruitment period from 3.5 to 5.5 years, the replacement of the DSMB statistician and editorial changes (current protocol version 5.0, dated 10 January 2020). This protocol amendment was approved by the ethics committees of the Medical University of Innsbruck (21 February 2020), the Institute of Clinical and Experimental Medicine and Thomayer Hospital (11 March 2020), and the RWTH Aachen (18 March 2020). As changes reflected in the third global protocol amendment are considered nonsubstantial in Spain, this amendment was not submitted to the Comités de Ética de la Investigación de los Hospitales Universitarios Virgen Macarena – Virgen del Rocío de Sevilla.

The fourth protocol amendment addresses modifications within the inclusion and exclusion criteria to improve patient recruitment and to exclude patients with confirmed acute SARS-CoV-2 infection, changes within the secondary variables and corresponding visit schedule to reflect clinical routine, editorial and organizational modifications (current protocol version 6.0, dated 16 July 2020). This protocol amendment was approved by the ethics committees of the Medical University of Innsbruck (25 September 2020), the Institute of Clinical and Experimental Medicine and Thomayer Hospital (09 September 2020), Comités de Ética de la Investigación de los Hospitales Universitarios Virgen Macarena – Virgen del Rocío de Sevilla (30 September 2020), and the RWTH Aachen (22 October 2020). Written informed consent will be obtained from all patients or their legal representatives, authorized persons, or relatives, depending on the local regulations. For details, refer to the “Methods/design” section, specifically the “Interventions and procedures” or “Enrolment” subsection. The approvals by the ethic committees mentioned above include the deferred consent procedure used in this study.

Consent for publication
Not applicable.

Competing interests
Authors: GM received grants/research support and honouraria/consultation fees from B. Braun Melsungen AG and Adrenomed and participated in company-sponsored speakers bureaus from B. Braun Melsungen AG, Edwards Life
Sciences, Philips and Adrenomed. GM acted as coordinator of the S3 guideline on volume therapy for the Association of the Scientific Medical Societies in Germany (AWMF, see [11]).

KZ received research grants, advisory and lecture honouraria, and financial support (education) for his department from Aesculap Akademie GmbH, Affinites Sante, Asta Kaci Pharma, B. Braun Melsungen AG, B. Braun Avitum AG, Bayer AG, Biotech AG, Christian Doppler Stiftung, CSL Behring GmbH, Cyto Sorbents GmbH, Edward Lifescience Corporation, Executive Insight AG, Fresenius Kabi GmbH, Fresenius Medical Care, Haemonetics Corporation, Hartmannverbund Landesverband, Health Advances GmbH, Heinem-Löwenstein GmbH, Hexal AG, INC Research, Johnson & Johnson, Josef Gassner, Maquet GmbH, Markus Lücke Kongress Organisation, Masimo International, med update GmbH, Medizin & Markt Gesundheitsnetzwerk, MSD Sharp & Dohme GmbH, Nordic Group, Nordic Pharma, Novo Nordisk Pharma GmbH, Pfizer Pharma GmbH, Pharmacosmos, Ratiopharm GmbH, Salvia Medical GmbH, Schering Stiftung, Schöchl Medical Österreich, Serumwerke, Verlag für Printmedien und PR, Forum Sanitas, Vifor Pharma GmbH, Wellington, Werfen. CI received reimbursement of registration fees and travel expenses for congress participation by B. Braun Melsungen AG and Baxter, as well as honouraria for participation in expert meetings by Fresenius.

KA received lecture honouraria from Fresenius, Baxter, LBF and Boehringer.

VC received lecture honouraria from Fresenius, B. Braun Melsungen AG, CSL Behring, AOP Orphan, Bard, AbbVie.

RD received advisory fees from B. Braun Melsungen AG.

RF received speaker fees and advisory fees from B. Braun Melsungen AG and Grifols.

DF received honouraria for consulting, lecture fees, and sponsoring for academic studies from Baxter, B. Braun Melsungen AG, CSL Behring, Instrumental Laboratories, LBF, Mitsubishi Pharma, Octapharm, Takeda and Teri-Innovation.

ZM was a member of the Pulsion medical advisory board and received lecture honouraria from Pulsion-Maquet (member of the Getinge Group), Biotech, CytoSorbents, and ThermoFisher. Currently, he is a member of the medical directors of CytoSorbents Europe.

PR declares that he has no competing interests.

MS declares that he has no competing interests.

TS received restricted grants from B. Braun Melsungen AG, Fresenius Kabi Deutschland GmbH and Fresenius Medical GmbH, Germany.

TD (Director Clinical Development Plasma Volume Replacement), SSch (Senior Scientific Manager Clinical Development), EvK (Vice President Preclinical and Clinical Development), and UB (Chief Medical Officer) are employed by B. Braun Melsungen AG.

TPS received research grants and lecture honouraria from B. Braun Melsungen AG.

DSMB Members:

The DRS academic department is receiving grant support from the Swiss National Science Foundation, Berne, Switzerland; the Swiss Society of Anaesthesiology and Reanimation (SGAR), Berne, Switzerland; the Swiss Foundation for Anaesthesia Research, Zurich, Switzerland; Vifor SA, Villars-sur-Glâne, Switzerland; and Vifor (International) AG, St. Gallen, Switzerland. DRS is co-chair of the ABC-Trauma Faculty, sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland; CSL Behring GmbH, Marburg, Germany; LBF Biomédicaments, Courtaboeuf Cedex, France; and Octapharma AG, Lachen, Switzerland. DRS received honouraria/travel support for consulting or lecturing from: Danubio University of Krems; Austria; US Department of Defense, Washington, USA; European Society of Anaesthesiology, Brussels; BE; Korean Society for Patient Blood Management, Seoul, Korea; Korean Society of Anaesthesiologists, Seoul, Korea; Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis, Paris, France; Baxalta Switzerland AG, Volketswil, Switzerland; Bayer AG, Zürich, Switzerland; B. Braun Melsungen AG, Melsungen, Germany; Boehringer Ingelheim GmbH, Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland; CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland; Celgene International II Sàrl, Couvet, Switzerland; Daiichi Sankyo AG, Thalwil, Switzerland; Haemonetics, Braintree, MA, USA; Instrumentation Laboratory (Werfen), Bedford, MA, USA; LBF Biomédicaments, Courtaboeuf Cedex, France; Merck Sharp & Dohme, Kenilworth, New Jersey, USA; PAION Deutschland GmbH, Aachen, Germany; Pharmacosmos A/S, Holbaek, Denmark; Pfizer AG, Zürich, Switzerland; Pierre Fabre Pharma, Aeschwil, Switzerland; Portola Schweiz GmbH, Aarau, Switzerland; Roche Diagnostics International Ltd, Reinach, Switzerland; Sarstedt AG & Co, Seefelden, Switzerland and Nürnberg, Germany; Shire Switzerland GmbH, Zug, Switzerland; Tem International GmbH, Munich, Germany; Vifor Pharma, Munich, Germany; Neuleyl sur Seine, France and Villars-sur-Glâne, Switzerland; Vifor (International) AG, St. Gallen, Switzerland; and Zentelli Pharma Holdings, Singapore, Singapore.

DRS received honoraria consultation with B. Braun Melsungen AG, Melsungen, Germany.

HS is employed by Pharmalog –Institut für klinische Forschung and contracted by B. Braun Melsungen AG, Melsungen, Germany, for statistical consulting services.

Author details

1 Klinik für Operative Intensivmedizin und Intermediate Care, Universitätshospital RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany. 2 Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätshospital RWTH Aachen, Goethe Universität, Theodor-Stern-Kai 7, 50936 Köln, Germany. 3 Université Côte d’Azur Service de Réanimation Polyvalente, Hôpital Pasteur 2 – CHU de Nice, 30 Voie Romaine, 06000 Nice, France. 4 Université de Nantes, CHU – L’Hôtel Dieu, 1, Place Alexis Ricordeau, 44003 Nantes Cedex 1, France. 5 Kajžská zdravotní, a.s., Masarykova nemocnice v Usti na Labe, o.z., Sociální péče 33161/12A, 401 13 Usti na Labe, Czech Republic. 6 Klinik für Intensivmedizin und Notfallmedizin, Klinikum Breiten-Mitte, St. Jürgen-Straße 1, 28177 Bremen, Germany. 7 Servicio de Medicina Intensiva, Hospital Universitari Vall d’Hebron, Passeig Vall d’Hebron, 119-129, 08035 Barcelona, Spain. 8 Allgemeine und Chirurgische Intensivstation, Medizinische Universität Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.

Received: 27 August 2020 Accepted: 4 May 2021

Published online: 02 June 2021

References

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55. https://doi.org/10.1378/chest.101.6.1644.

2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. The Global Burden of Disease Study. Lancet. 2020;395(10219): 200–11. https://doi.org/10.1016/S0140-6736(19)32098-7.

3. SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016;42(12):1980–9. https://doi.org/10.1007/s00134-016-4504-3.

4. Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol. 2003;20(6):429–42. https://doi.org/10.1017/S0266462303306000-00002.

5. Dellinger RP, Levy MM, Carlet JM, Bion J, Lucet HC, Parke MD, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 2008;34(1):17–60. https://doi.org/10.1007/s00134-007-0934-2.

6. Schorr CA, Zanotti S, Dellinger RP. Severe sepsis and septic shock: management and performance improvement. Virulence. 2014;5(1):190–9. https://doi.org/10.4161/viru.27409.

7. Dellinger RP. The Surviving Sepsis Campaign: where have we been and where are we going? Cleve Clin J Med. 2015;82(4):237–44. https://doi.org/10.3949/ccjm.82gr.15001.
